PRODUCT CODE: ET1703-61

Recombinant Podoplanin Monoclonal Antibody (ET1703-61)

  • Recombinant

Applications

  • WB

  • IHC-P

REACTIVITY

  • Human

Western blot analysis of Podoplanin on human lung cells lysates using anti-Podoplanin antibody at 1/500 dilution.
  • Western blot analysis of Podoplanin on human lung cells lysates using anti-Podoplanin antibody at 1/500 dilution.
  • Immunohistochemical analysis of paraffin-embedded human lung tissue using anti-Podoplanin antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using anti-Podoplanin antibody. Counter stained with hematoxylin.
Western blot analysis of Podoplanin on human lung cells lysates using anti-Podoplanin antibody at 1/500 dilution.

Applications

  • WB

  • IHC-P

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Recombinant Rabbit monoclonal primary

Product Name

Recombinant Podoplanin Monoclonal Antibody (ET1703-61)

Immunogen

Recombinant protein

Host

Rabbit

Positive Control

Human lung cells lysates, human lung tissue, human colon cancer tissue.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

JM31-21

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 ug/ul

PURIFICATION

Protein A purified.

MOLECULAR WEIGHT

36 kDa

Isotype

IgG

APPLICATION DILUTION

  • WB

  • 1:2,000-1:5,000

  • IHC-P

  • 1:50-1:200

TARGET

UNIPROT #

PROTEIN NAME

Podoplanin

GENE NAME

PDPN

SYNONYMS

Gp36, T1A

SEQUENCE SIMILARITIES

Belongs to the podoplanin family.

TISSUE SPECIFICITY

Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas.

POST-TRANSLATIONAL MODIFICATION

Extensively O-glycosylated. Contains sialic acid residues. O-glycosylation is necessary for platelet aggregation activity. Disialylated at Thr-52; sialic acid is critical for platelet-aggregating activity and for CLEC1B interaction.; The N-terminus is blocked.; Cleaved by a metalloprotease within its extracellular (EC) domain, generating a membrane-bound C-terminal fragment (PCTF33) and an extracellular fragment. The resulting membrane-bound C-terminal fragment (PCTF33) is further processed between Val-150 and Val-151 by PSEN1/gamma-secretase generating the intracellular domain of podoplanin (PICD).

SUBCELLULAR LOCATION

[Podoplanin]: Membrane; Single-pass type I membrane protein; Single-pass type I membrane protein; Single-pass type I membrane protein; Single-pass type I membrane protein; Single-pass type I membrane protein. Apical cell membrane. Basolateral cell membrane. Cell projection, invadopodium. Note=Localized to actin-rich microvilli and plasma membrane projections such as filopodia, lamellipodia and ruffles (By similarity). Association to the lipid rafts is required for PDPN-induced epithelial to mesenchymal transition (EMT). Colocalizes with CD9 in tetraspanin microdomains. Localized at invadopodium adhesion rings in tumor cell. Association to the lipid rafts is essential for PDPN recruitment to invadopodia and ECM degradation.; [29kDa cytosolic podoplanin intracellular domain]: Cytoplasm, cytosol.

FUNCTION

Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation. Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN. Through MSN or EZR interaction promotes epithelial-mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness. Interaction with CD44 promotes directional cell migration in epithelial and tumor cells. In lymph nodes (LNs), controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR; MSN and RDX) and MYL9 activation through association with unknown transmembrane proteins. Engagement of CLEC1B by PDPN promotes FRCs relaxation by blocking lateral membrane interactions leading to reduction of ERM proteins (EZR; MSN and RDX) and MYL9 activation (By similarity). Through binding with LGALS8 may participate in connection of the lymphatic endothelium to the surrounding extracellular matrix. In keratinocytes, induces changes in cell morphology showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion. Controls invadopodia stability and maturation leading to efficient degradation of the extracellular matrix (ECM) in tumor cells through modulation of RHOC activity in order to activate ROCK1/ROCK2 and LIMK1/LIMK2 and inactivation of CFL1. Required for normal lung cell proliferation and alveolus formation at birth (By similarity). Does not function as a water channel or as a regulator of aquaporin-type water channels. Does not have any effect on folic acid or amino acid transport (By similarity).